CLARITY-101NCT07849231
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 4 → 36 locations
- Minor Study title shortened, about 4 words
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the protocol defined starting dose and dosing schedule to identify the maximum tolerated dose and/or recommended dose(s) for expansion.
DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined recommended dose(s) for expansion based on Part 1.
DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined dose and regimen, but in combination with an oral tablet of ruxolitinib, a standard of care drug approved therapy for the treatment of MF.
Drugs: DMR-001, Ruxolitinib
Sites
36 sites in 2 countries
United States 25, Australia 11